0.00
+14.29%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Premier Graphene
Its shares trade under the ticker BIEI. It has been listed since 23 February 2012. In the fiscal year to 31 December 2020, it reported revenue of $1,018 and a net loss of $403,167. At that date it held total assets of $4,601 and shareholders' equity of −$2.2m.
Premier Biomedical, Inc. is a research-based company, which engages in the development and discovery of medical products. The company is headquartered in Whitefish, Montana. The company went IPO on 2012-02-23. The firm intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer's disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. The company also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Feb 2012
- Website
- premierbiomedical.com ↗
Leadership
Pay as last reported
- David CaplanPresident, Treasurer, Secretary, Director, since 2020
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Premier Biomedical Inc has several key strengths that contribute to its success in the biomedical industry. Firstly, the company has a strong portfolio of innovative and technologically advanced biomedical products. These products are developed through extensive research and development efforts, ensuring their effectiveness and market competitiveness. Secondly, Premier Biomedical Inc boasts a talented team of professionals with expertise in various areas of biomedicine. This skilled workforce allows the company to continuously improve its products and respond to evolving market demands. Additionally, the company has established strong relationships with medical institutions, distributors, and other industry players. This network helps Premier Biomedical Inc reach a wider customer base and ensures a consistent revenue stream.
Weaknesses
- Despite its strengths, Premier Biomedical Inc faces certain weaknesses that hinder its overall performance. One significant weakness is the company's limited financial resources. While Premier Biomedical Inc has developed innovative products, it may struggle to fund large-scale production and distribution efforts. This could potentially prevent the company from capitalizing on market opportunities and expanding its market share. Another weakness is the company's relatively small market presence compared to some of its competitors. Limited brand recognition and market penetration can make it challenging for Premier Biomedical Inc to compete effectively, especially in highly regulated and competitive markets.
Opportunities
- Premier Biomedical Inc operates in an industry with several promising opportunities. The growing demand for advanced biomedical solutions presents a significant opportunity for Premier Biomedical Inc to expand its customer base and increase sales. Additionally, there is an increasing trend towards personalized medicine, which aligns with the company's focus on developing targeted therapies. By capitalizing on this trend, Premier Biomedical Inc can position itself as a leader in personalized medicine and gain a competitive advantage. Moreover, strategic partnerships and collaborations with research institutions, pharmaceutical companies, and healthcare providers can provide Premier Biomedical Inc with access to additional resources, expertise, and market opportunities. Such collaborations can accelerate product development, enhance market reach, and boost revenue growth.
Threats
- Premier Biomedical Inc is not immune to external threats that could adversely impact its business. One significant threat is the stringent regulatory environment governing the biomedical industry. Compliance with various regulations and obtaining necessary approvals can be time-consuming and costly. Failure to comply with these regulations can result in delays in product launches or even rejection, affecting the company's revenue potential. Furthermore, intense competition within the biomedical industry poses a threat to Premier Biomedical Inc's market position. Competitors with larger market shares and greater resources may develop similar products or technologies, potentially eroding Premier Biomedical Inc's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.